Chronic Myelomonocytic Leukemia (CMML) is an indication for drug development with over 70 pipeline drugs currently active. According to GlobalData, preregistered drugs for Chronic Myelomonocytic Leukemia (CMML) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Chronic Myelomonocytic Leukemia (CMML) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Chronic Myelomonocytic Leukemia (CMML) overview
Chronic Myelomonocytic Leukemia (CMML) is a type of rare blood cancer that combines features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). It primarily affects the bone marrow and blood cells, resulting in the overproduction of abnormal monocytes (a type of white blood cell) and other blood cells. CMML is characterized by an increased number of monocytes in the blood and bone marrow, along with varying degrees of abnormal changes in other blood cell types. This disease is typically diagnosed in older adults and can have a range of symptoms or may be asymptomatic in some cases. The symptoms of CMML can include fatigue, weakness, recurrent infections, fever, enlarged spleen or liver, easy bruising or bleeding, and night sweats. However, some individuals might not exhibit any symptoms during the early stages of the disease.
For a complete picture of PTSR and LoA scores for drugs in Chronic Myelomonocytic Leukemia (CMML), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
